These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 14711930)

  • 1. Suppression of acute herpetic pain-related responses by the kappa-opioid receptor agonist (-)-17-cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-beta-[n-methyl-3-trans-3-(3-furyl) acrylamido] morphinan hydrochloride (TRK-820) in mice.
    Takasaki I; Suzuki T; Sasaki A; Nakao K; Hirakata M; Okano K; Tanaka T; Nagase H; Shiraki K; Nojima H; Kuraishi Y
    J Pharmacol Exp Ther; 2004 Apr; 309(1):36-41. PubMed ID: 14711930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel kappa-opioid receptor agonist TRK-820 has no affect on the development of antinociceptive tolerance to morphine in mice.
    Tsuji M; Yamazaki M; Takeda H; Matsumiya T; Nagase H; Tseng LF; Narita M; Suzuki T
    Eur J Pharmacol; 2000 Apr; 394(1):91-5. PubMed ID: 10771039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of mu-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice.
    Mizoguchi H; Hung KC; Leitermann R; Narita M; Nagase H; Suzuki T; Tseng LF
    Eur J Pharmacol; 2003 Feb; 461(1):35-9. PubMed ID: 12568913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system.
    Umeuchi H; Togashi Y; Honda T; Nakao K; Okano K; Tanaka T; Nagase H
    Eur J Pharmacol; 2003 Sep; 477(1):29-35. PubMed ID: 14512095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological properties of TRK-820 on cloned mu-, delta- and kappa-opioid receptors and nociceptin receptor.
    Seki T; Awamura S; Kimura C; Ide S; Sakano K; Minami M; Nagase H; Satoh M
    Eur J Pharmacol; 1999 Jul; 376(1-2):159-67. PubMed ID: 10440101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the antinociceptive effects of TRK-820 in the rat.
    Endoh T; Tajima A; Suzuki T; Kamei J; Narita M; Tseng L; Nagase H
    Eur J Pharmacol; 2000 Jan; 387(2):133-40. PubMed ID: 10650153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820.
    Togashi Y; Umeuchi H; Okano K; Ando N; Yoshizawa Y; Honda T; Kawamura K; Endoh T; Utsumi J; Kamei J; Tanaka T; Nagase H
    Eur J Pharmacol; 2002 Jan; 435(2-3):259-64. PubMed ID: 11821035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.
    Wang Y; Tang K; Inan S; Siebert D; Holzgrabe U; Lee DY; Huang P; Li JG; Cowan A; Liu-Chen LY
    J Pharmacol Exp Ther; 2005 Jan; 312(1):220-30. PubMed ID: 15383632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRK-820, a selective kappa-opioid agonist, produces potent antinociception in cynomolgus monkeys.
    Endoh T; Tajima A; Izumimoto N; Suzuki T; Saitoh A; Suzuki T; Narita M; Kamei J; Tseng LF; Mizoguchi H; Nagase H
    Jpn J Pharmacol; 2001 Mar; 85(3):282-90. PubMed ID: 11325021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates.
    Ko MC; Husbands SM
    J Pharmacol Exp Ther; 2009 Jan; 328(1):193-200. PubMed ID: 18842704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a structurally novel opioid kappa-agonist derived from 4,5-epoxymorphinan.
    Nagase H; Hayakawa J; Kawamura K; Kawai K; Takezawa Y; Matsuura H; Tajima C; Endo T
    Chem Pharm Bull (Tokyo); 1998 Feb; 46(2):366-9. PubMed ID: 9501472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of repeated administration of TRK-820, a kappa-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions.
    Suzuki T; Izumimoto N; Takezawa Y; Fujimura M; Togashi Y; Nagase H; Tanaka T; Endoh T
    Brain Res; 2004 Jan; 995(2):167-75. PubMed ID: 14672806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel kappa-opioid receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice.
    Tsuji M; Takeda H; Matsumiya T; Nagase H; Narita M; Suzuki T
    Life Sci; 2001 Mar; 68(15):1717-25. PubMed ID: 11270618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific down-regulation of spinal mu-opioid receptor and reduced analgesic effects of morphine in mice with postherpetic pain.
    Takasaki I; Nojima H; Shiraki K; Kuraishi Y
    Eur J Pharmacol; 2006 Nov; 550(1-3):62-7. PubMed ID: 17026987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of TRK-820, a selective kappa opioid receptor agonist, on rat schizophrenia models.
    Yoshikawa S; Hareyama N; Ikeda K; Kurokawa T; Nakajima M; Nakao K; Mochizuki H; Ichinose H
    Eur J Pharmacol; 2009 Mar; 606(1-3):102-8. PubMed ID: 19374836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease.
    Ikeda K; Yoshikawa S; Kurokawa T; Yuzawa N; Nakao K; Mochizuki H
    Eur J Pharmacol; 2009 Oct; 620(1-3):42-8. PubMed ID: 19686730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent antinociceptive effects of TRK-820, a novel kappa-opioid receptor agonist.
    Endoh T; Matsuura H; Tajima A; Izumimoto N; Tajima C; Suzuki T; Saitoh A; Suzuki T; Narita M; Tseng L; Nagase H
    Life Sci; 1999; 65(16):1685-94. PubMed ID: 10573186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Intrathecal κ-Opioid Receptor Agonist on Morphine-Induced Itch and Antinociception in Mice.
    Sakakihara M; Imamachi N; Saito Y
    Reg Anesth Pain Med; 2016; 41(1):69-74. PubMed ID: 26587674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
    Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
    J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel kappa-opioid receptor agonist, TRK-820, blocks the development of physical dependence on morphine in mice.
    Tsuji M; Takeda H; Matsumiya T; Nagase H; Yamazaki M; Narita M; Suzuki T
    Life Sci; 2000; 66(25):PL353-8. PubMed ID: 10894094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.